DEF 14A: Protagenic Therapeutics Seeks Stockholder Approval for Reverse Stock Split to Maintain Nasdaq Listing

Protagenic Therapeutics is asking stockholders to approve a reverse stock split to maintain compliance with Nasdaq's minimum bid price requirement and potentially increase investor interest.

Summary

• Protagenic Therapeutics is seeking stockholder approval for a reverse stock split of its common stock.
• The proposed reverse stock split ratio would range from 1-for-10 to 1-for-20, with the exact ratio to be determined by the Board of Directors.
• The company aims to regain compliance with Nasdaq's minimum $1.00 per share bid price requirement to avoid delisting.
• The Board believes a higher stock price could attract investors and help retain employees.
• Stockholders will also vote on a proposal to adjourn the special meeting, if necessary, to solicit additional proxies for the reverse stock split proposal.
• The special meeting is scheduled for April 18, 2025, and will be held virtually.

Sentiment

Score: 5

Explanation: The document is neutral in tone, presenting the facts of the proposed reverse stock split and the reasons behind it. While the company faces challenges, the document focuses on a potential solution.

Positives

• The Board believes that the reverse stock split is the best means of ensuring compliance with the $1.00 per share of Common Stock minimum bid price requirement for continued listing on The Nasdaq Capital Market and avoid delisting.
• The Board of Directors believes that continued listing on The Nasdaq Capital Market provides overall credibility to an investment in our stock, given the stringent listing and disclosure requirements of The Nasdaq Capital Market.
• Increasing visibility of our stock among a larger pool of potential investors could result in higher trading volumes.
• The Board of Directors believes that a higher stock price, which may be achieved through a reverse stock split, could help generate investor interest in the Company and help attract, retain, and motivate employees.

Negatives

• There is no assurance that the market price per share of our Common Stock after the reverse stock split will rise in proportion to the reduction in the number of shares of our Common Stock issued immediately before the reverse stock split.
• There is no assurance that the reverse stock split will result in a per share price that will increase the level of investment in our Common Stock by institutional investors or increase analyst and broker interest in our Company.
• There is no assurance that the reverse stock split will result in a per share price that will increase our ability to attract and retain employees and other service providers.
• There is no assurance that the market price per share of our Common Stock will either exceed or remain in excess of the $1.00 minimum bid price as required by Nasdaq, or that we will otherwise meet the requirements of Nasdaq for continued inclusion for trading on The Nasdaq Capital Market.
• Nasdaq may delist our Common Stock prior to the vote at the Special Meeting as the Nasdaq Hearings Panels final decision may arrive before the Special Meeting date.

Risks

• The reverse stock split may not result in a sustained increase in the per share price of the common stock.
• The market price of the common stock may decline after the reverse stock split, potentially leading to a greater percentage decline in market capitalization.
• The liquidity of the common stock could be adversely affected by the reduced number of shares outstanding after the reverse stock split.
• The company may not be able to satisfy all of the other requirements for continued listing on The Nasdaq Capital Market or other stock exchange, even if the reverse stock split is effected.
• The company received written notice from Nasdaq notifying the Company that it was not in compliance with the requirement of Nasdaq Listing Rule 5550(a)(2) for continued listing on the Nasdaq Capital Market as a result of the closing bid price of our Common Stock being below $1.00 per share for 30 consecutive business days.

Future Outlook

The company's future depends on regaining compliance with Nasdaq listing requirements and potentially raising additional capital. The reverse stock split is intended to help achieve these goals, but its success is not guaranteed.

Management Comments

• The Board of Directors believes that effecting a reverse stock split may be the best means of increasing and maintaining the price of our Common Stock to above $1.00 per share in compliance with the Bid Price Rule for continued listing on The Nasdaq Capital Market.

Industry Context

Reverse stock splits are a common strategy for companies facing delisting from major exchanges due to low stock prices. Other companies in the biotech industry facing similar challenges may consider this approach.

Comparison to Industry Standards

• Many small-cap biotech companies with promising but yet-to-be-commercialized technologies face similar challenges in maintaining Nasdaq listing compliance.
• Companies like [Comparable Company A] and [Comparable Company B] have previously implemented reverse stock splits to address minimum bid price requirements.
• The success of a reverse stock split in maintaining listing and attracting investors varies widely and depends on the company's underlying fundamentals and market conditions.

Stakeholder Impact

• Shareholders will be impacted by the reverse stock split, potentially seeing a change in the number of shares they own and the per-share price.
• Employees may benefit from a higher stock price, which could improve morale and attract new talent.
• The company's ability to raise capital and fund its operations could be affected by its Nasdaq listing status.

Next Steps

• Stockholders will vote on the reverse stock split proposal at the Special Meeting on April 18, 2025.
• If approved, the Board of Directors will determine the exact reverse stock split ratio and timing.
• The company must regain compliance with Nasdaq Listing Rules 5550(a)(2) and 5550(b)(1) on or before April 28, 2025.

Key Dates

Keywords

reverse stock split, Nasdaq, listing, common stock, proxy, stockholders, PTIX, compliance